Back

Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial

2 September 2019 (14:44 - 14:58)
Organised by:
Congress Presentation Part of: Progress in secondary prevention - New treatments Secondary Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Thomas Vanassche

University Hospitals (UZ) Leuven, Leuven (Belgium)

4 More presentations in this session

Presentation thumbnail
Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis
Mr A. Roddick (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials
Miss O. Ghosh-Swaby (London, CA)
Abstract Slides Video
Presentation thumbnail
Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy
Professor M. Roe (Chapel Hill, US)
Abstract Slides Video
Presentation thumbnail
Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment
Doctor R. Diaz (Rosario, AR)
Abstract Slides Video

Access the full session

Session thumbnail
Progress in secondary prevention - New treatments

The Event

Event poster

ESC Congress 2019

2 September 2019 14:44 CET
You may be interested in
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources